ALRN
Aileron Therapeutics
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 47.90M; Volume: 117.06K; AvgVol 3m: 789.75K; Beta: –;
Cost estimate:
P/E: –; EPS: -0.92; EPS growth quarter/prev quarter: 46.00%;
EPS growth this year: 44.10%; EPS growth past 5 years: -1.80%;
EPS ttm: -0.92;
P/S: ; P/B: 2.32; P/Cashflow: 2.73; P/FCF: ;
Sales: –; Sales growth quarter/prev quarter: ; Sales growth past 5 years: ;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -97.70%; ROE – return on equity: -160.00%; LT Debt/Equity: 0.01; Total Debt/Equity: 0.02;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 1.10%; Insider Transactions:;
Institutional Ownership: 17.60%; Institutional Transactions: 38.35%;
Data update: 07.10.2020.